OncoSec Medical Incorporated ONCSQ
OTC PK
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.46% | -31.69% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.19% | -25.62% | -- | -- | -- |
| Operating Income | 25.19% | 25.62% | -- | -- | -- |
| Income Before Tax | 24.55% | 19.02% | -- | -- | -- |
| Income Tax Expenses | -38.22% | -38.13% | -- | -- | -- |
| Earnings from Continuing Operations | 28.25% | 22.32% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.25% | 22.32% | -- | -- | -- |
| EBIT | 25.19% | 25.62% | -- | -- | -- |
| EBITDA | 25.33% | 25.77% | -- | -- | -- |
| EPS Basic | 34.50% | 30.08% | -- | -- | -- |
| Normalized Basic EPS | 32.10% | 30.15% | -- | -- | -- |
| EPS Diluted | 34.50% | 30.08% | -- | -- | -- |
| Normalized Diluted EPS | 32.10% | 30.15% | -- | -- | -- |
| Average Basic Shares Outstanding | 13.02% | 9.15% | -- | -- | -- |
| Average Diluted Shares Outstanding | 13.02% | 9.15% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |